DK1237886T3 - Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor - Google Patents

Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor

Info

Publication number
DK1237886T3
DK1237886T3 DK00983240T DK00983240T DK1237886T3 DK 1237886 T3 DK1237886 T3 DK 1237886T3 DK 00983240 T DK00983240 T DK 00983240T DK 00983240 T DK00983240 T DK 00983240T DK 1237886 T3 DK1237886 T3 DK 1237886T3
Authority
DK
Denmark
Prior art keywords
carboxylic acid
acid compound
nmda receptor
quinoline carboxylic
compound active
Prior art date
Application number
DK00983240T
Other languages
Danish (da)
English (en)
Inventor
Alessandra Orlandi
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Application granted granted Critical
Publication of DK1237886T3 publication Critical patent/DK1237886T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
DK00983240T 1999-12-08 2000-12-07 Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor DK1237886T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
DK1237886T3 true DK1237886T3 (da) 2006-08-14

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00983240T DK1237886T3 (da) 1999-12-08 2000-12-07 Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor

Country Status (30)

Country Link
US (2) US6713491B2 (cs)
EP (1) EP1237886B1 (cs)
JP (1) JP4311901B2 (cs)
KR (1) KR100788579B1 (cs)
CN (1) CN1325488C (cs)
AR (1) AR030923A1 (cs)
AT (1) ATE323691T1 (cs)
AU (1) AU769232B2 (cs)
BR (1) BR0016235A (cs)
CA (1) CA2393303C (cs)
CO (1) CO5251474A1 (cs)
CY (1) CY1106105T1 (cs)
CZ (1) CZ301052B6 (cs)
DE (1) DE60027461T2 (cs)
DK (1) DK1237886T3 (cs)
ES (1) ES2257343T3 (cs)
GB (1) GB9929037D0 (cs)
HK (1) HK1047436B (cs)
HU (1) HUP0203650A3 (cs)
IL (2) IL150010A0 (cs)
MX (1) MXPA02005802A (cs)
MY (1) MY129892A (cs)
NO (1) NO323263B1 (cs)
PL (1) PL356713A1 (cs)
PT (1) PT1237886E (cs)
TN (1) TNSN00240A1 (cs)
TR (1) TR200201503T2 (cs)
TW (1) TW524804B (cs)
WO (1) WO2001042238A1 (cs)
ZA (1) ZA200204492B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100506811C (zh) * 2003-04-25 2009-07-01 日本化学医药株式会社 (2s,3s)-3-[[(1s)-1-异丁氧基甲基-3-甲基丁基]氨基甲酰基]环氧乙烷-2-甲酸盐
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
EP3056492B1 (en) * 2004-10-08 2021-09-22 AbbVie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
DK1868581T3 (da) * 2005-04-11 2012-07-09 Abbott Lab Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
BR9610733A (pt) 1995-09-29 1999-07-13 Glaxo Wellcome Spa Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
ZA200204492B (en) 2004-06-30
GB9929037D0 (en) 2000-02-02
TNSN00240A1 (en) 2002-05-30
CN1325488C (zh) 2007-07-11
DE60027461T2 (de) 2006-09-28
EP1237886A1 (en) 2002-09-11
DE60027461D1 (de) 2006-05-24
IL150010A (en) 2009-09-01
KR100788579B1 (ko) 2007-12-26
CO5251474A1 (es) 2003-02-28
IL150010A0 (en) 2002-12-01
HK1047436A1 (en) 2003-02-21
BR0016235A (pt) 2002-08-27
AR030923A1 (es) 2003-09-03
HUP0203650A3 (en) 2004-01-28
KR20020086854A (ko) 2002-11-20
PL356713A1 (en) 2004-06-28
ES2257343T3 (es) 2006-08-01
CY1106105T1 (el) 2011-06-08
US20030008899A1 (en) 2003-01-09
CZ301052B6 (cs) 2009-10-21
EP1237886B1 (en) 2006-04-19
PT1237886E (pt) 2006-07-31
TR200201503T2 (tr) 2002-10-21
MY129892A (en) 2007-05-31
US6713491B2 (en) 2004-03-30
TW524804B (en) 2003-03-21
JP4311901B2 (ja) 2009-08-12
NO20022682D0 (no) 2002-06-06
AU2006001A (en) 2001-06-18
HUP0203650A2 (hu) 2003-03-28
NO20022682L (no) 2002-07-17
AU769232B2 (en) 2004-01-22
CA2393303C (en) 2009-10-20
MXPA02005802A (es) 2004-08-12
ATE323691T1 (de) 2006-05-15
CN1407980A (zh) 2003-04-02
WO2001042238A1 (en) 2001-06-14
CZ20021981A3 (cs) 2003-01-15
NO323263B1 (no) 2007-02-19
HK1047436B (en) 2006-07-21
CA2393303A1 (en) 2001-06-14
US20040162313A1 (en) 2004-08-19
JP2003516403A (ja) 2003-05-13
US6943176B2 (en) 2005-09-13

Similar Documents

Publication Publication Date Title
FI20002767L (fi) Jodoniumsuolat latentteina happodonoreina
NO20024387L (no) Karboksylsyrederivater som IP-antagonister
DK0981527T3 (da) Salt af et naphthyridincarboxylsyrederivat
DK1163207T3 (da) Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin
BR0005305B1 (pt) absorvente higiÊnico composto.
DK0888317T3 (da) Substituerede 4-hydroxy-phenylalkansyrederivater med agonistaktivitet over for PPAR-gamma
CY2009011I1 (el) Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
NO20016319L (no) VLA-4 inhibitor-forbindelser
FI990754A0 (fi) Tiedonhallintamekanismi projektisuunnittelua varten
DK1100332T3 (da) Herbicide Phenoxypropionsyre-N-alkyl-N-2-fluorphenylamidforbindelser
NO20025136L (no) Cykloheksylaminderivat som subtype selektive NMDA- reseptorantagonister
DK1328499T3 (da) Fremgangsmåde til fremstilling af carboxylsyresalte
NO331228B1 (no) Anvendelse av en sammensetning som omfatter et ketotifensalt
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
DK1237886T3 (da) Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor
IS6400A (is) Kristallað form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýlfenýl}etoxý)fenýl]própanónsýra
DK1165547T3 (da) Substituerede benzoylpyrazoler som herbicider
NO20020774D0 (no) Farmasöytisk middel omfattende et benzamid-derivat som aktiv forbindelse
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
DK1159258T3 (da) Amidforbindelser til potensering af kolinerg aktivitet
EE200100646A (et) Melagatraani peaaegu kristalne vorm
DK1114050T3 (da) Fremgangsmåde til fremstilling af et naphthyridincarboxylsyrederivat (methansulfonat-sesquihydrat)
NO20021043L (no) Mellomprodukter for fremstilling av kinolonkarboksylsyre- derivater
TR200001121T2 (tr) Antiromatizmal madde.
EP1043311A4 (en) BIPHENYLAMIDINE DERIVATIVES